Literature DB >> 16450381

Suppression of cortical spreading depression in migraine prophylaxis.

Cenk Ayata1, Hongwei Jin, Chiho Kudo, Turgay Dalkara, Michael A Moskowitz.   

Abstract

OBJECTIVE: Topiramate, valproate, propranolol, amitriptyline, and methysergide have been widely prescribed for migraine prophylaxis, but their mechanism or site of action is uncertain. Cortical spreading depression (CSD) has been implicated in migraine and as a headache trigger and can be evoked in experimental animals by electrical or chemical stimulation. We hypothesized that migraine prophylactic agents suppress CSD as a common mechanism of action.
METHODS: Rats were treated either acutely or chronically over weeks and months, with one of the above migraine prophylactic drugs, vehicle, or D-propranolol, a clinically ineffective drug. The impact of treatment was determined on the frequency of evoked CSDs after topical potassium application or on the incremental cathodal stimulation threshold to evoke CSD.
RESULTS: Chronic daily administration of migraine prophylactic drugs dose-dependently suppressed CSD frequency by 40 to 80% and increased the cathodal stimulation threshold, whereas acute treatment was ineffective. Longer treatment durations produced stronger CSD suppression. Chronic D-propranolol treatment did not differ from saline control.
INTERPRETATION: Our data suggest that CSD provides a common therapeutic target for widely prescribed migraine prophylactic drugs. Assessing CSD threshold may prove useful for developing new prophylactic drugs and improving upon existing ones.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16450381     DOI: 10.1002/ana.20778

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  157 in total

1.  Migraine mutations increase stroke vulnerability by facilitating ischemic depolarizations.

Authors:  Katharina Eikermann-Haerter; Jeong Hyun Lee; Izumi Yuzawa; Christina H Liu; Zhipeng Zhou; Hwa Kyoung Shin; Yi Zheng; Tao Qin; Tobias Kurth; Christian Waeber; Michel D Ferrari; Arn M J M van den Maagdenberg; Michael A Moskowitz; Cenk Ayata
Journal:  Circulation       Date:  2011-12-05       Impact factor: 29.690

Review 2.  Pathophysiology of medication-overuse headache: implications from animal studies.

Authors:  Saknan Bongsebandhu-phubhakdi; Anan Srikiatkhachorn
Journal:  Curr Pain Headache Rep       Date:  2012-02

3.  Tonabersat: a cortical spreading depression inhibitor as potential pharmacologic prophylaxis in migraine with aura.

Authors:  Ivan Garza
Journal:  Curr Neurol Neurosci Rep       Date:  2010-01       Impact factor: 5.081

Review 4.  Transcranial magnetic simulation in the treatment of migraine.

Authors:  Richard B Lipton; Starr H Pearlman
Journal:  Neurotherapeutics       Date:  2010-04       Impact factor: 7.620

5.  Decade in review-migraine: incredible progress for an era of better migraine care.

Authors:  Peter J Goadsby
Journal:  Nat Rev Neurol       Date:  2015-10-27       Impact factor: 42.937

6.  Association of benign recurrent vertigo and migraine in 208 patients.

Authors:  Y-H Cha; H Lee; L S Santell; R W Baloh
Journal:  Cephalalgia       Date:  2009-01-16       Impact factor: 6.292

Review 7.  The cerebellum and migraine.

Authors:  Maurice Vincent; Nouchine Hadjikhani
Journal:  Headache       Date:  2007-06       Impact factor: 5.887

Review 8.  CGRP and migraine: could PACAP play a role too?

Authors:  Eric A Kaiser; Andrew F Russo
Journal:  Neuropeptides       Date:  2013-10-23       Impact factor: 3.286

Review 9.  Refining the Benefit/Risk Profile of Anti-Epileptic Drugs in Headache Disorders.

Authors:  Michael J Marmura; Aliza S Kumpinsky
Journal:  CNS Drugs       Date:  2018-08       Impact factor: 5.749

Review 10.  Cortical spreading depression and migraine.

Authors:  Andrew C Charles; Serapio M Baca
Journal:  Nat Rev Neurol       Date:  2013-09-17       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.